Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00494169 · ClinicalTrials.gov registry record

Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders

A clinical trial, sponsored by Massachusetts General Hospital.

Completed
Registry status
4,042
Enrollment target

NCT00494169: Completed study, sponsored by Massachusetts General Hospital.

NCT00494169 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 4,042 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00494169 has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
4,042 participants
Enrollment target

Study Summary

The aims of this study are: 1) to identify genes that play a role in human pubertal development and reproduction, 2) to characterize the phenotypic spectrum of patients with these gene defects, and 3) to discern the mode of inheritance for disorders caused by these gene defects. We are specifically interested in genes that cause Kallmann syndrome, idiopathic hypogonadotropic hypogonadism (IHH), precocious (early) puberty, and delayed puberty. Individuals do not have to travel to Boston to participate in this study.

Trial Details

FieldValue
Enrollment Target 4,042 participants
Start Date 1999-01
Est. Completion 2022-02
Massachusetts General Hospital

2,032 total trials

What the finished NCT00494169 record still lists

NCT00494169 is an observational study that tracks outcomes without assigning an intervention. Its 4,042 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT00494169 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00494169 about?

NCT00494169 is a clinical study titled "Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders". The aims of this study are: 1) to identify genes that play a role in human pubertal development and reproduction, 2) to characterize the phenotypic spectrum of patients with these gene defects, and 3) to discern the mode of inheritance for disorders caused by these gene defects. We are specifically ...

What is the current status of trial NCT00494169?

This trial is currently completed. The enrollment target is 4,042 participants. The study started on 1999-01. Estimated completion is 2022-02.

Who is sponsoring clinical trial NCT00494169?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00227253 · 4,000 participants

    Chromosome 18 Clinical Research Center

  • NCT00811148 · 4,000 participants

    Florida Center for Brain Tumor Research

  • NCT00897117 · 4,000 participants

    Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

  • NCT00899301 · 4,000 participants

    Collecting and Storing Tissue Samples From Women With or Without Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00494169, the US trial registry maintained by the National Library of Medicine. NCT00494169 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.